API | seltorexant

seltorexant Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Seltorexant, also known by its developmental code names MIN-202 and JNJ-42847922, is an orexin antagonist medication which is under development for the treatment of depression and insomnia. It is a selective antagonist of the orexin OX2 receptor (2-SORA). The medication is taken by mouth. As of February 2022, seltorexant is in phase 3 clinical trials for treatment of major depressive disorder (MDD) and phase 2 trials for treatment of insomnia. It was also under investigation for the treatment of sleep apnea, but no recent development has been reported for this indication. Seltorexant is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceuticals. ^Wikipedia

Chemistry

SMILES: Cc1cc(C)nc(N2CC3CN(C(=O)c4c(F)cccc4-n4nccn4)CC3C2)n1
InChIKey: SQOCEMCKYDVLMM-UHFFFAOYSA-N
Mol. Mass: 407.45
ALogP: 2.02 Partition coefficient
ChEMBL Molecule:
seltorexant

More Chemistry

Pharmacology

Mechanisms of Action:
- Orexin receptor type 1 (Homo sapiens) ^UniProt
- Orexin receptor type 2 (Homo sapiens) ^UniProt
- Orexin receptor type 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

jnj-42847922

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Alzheimer Disease (Phase 2)

Depressive Disorder, Major (Phase 3)

Healthy Volunteers (Phase 1)

Kidney Failure, Chronic (Phase 1)

Liver Diseases (Phase 1)

Sleep Apnea, Obstructive (Phase 1)

Sleep Initiation and Maintenance Disorders (Phase 2)

Substance Abuse, Oral (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 32
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue